v3.26.1
Consolidated Statements of Mezzanine and Stockholders’ Equity - USD ($)
$ in Thousands
Total
Conversion Of Convertible Preferred Stock
Series C Preferred Stock
Series D Preferred Stock
Series E Preferred Stock
AlmataBio Transaction
AlmataBio Transaction
Series C Preferred Stock
Private Placement
Series C Preferred Stock
Private Placement
Series D Preferred Stock
Private Placement
Series E Preferred Stock
Common stock
Common stock
Conversion Of Convertible Preferred Stock
Common stock
AlmataBio Transaction
Series C preferred stock
Series C Preferred Stock
Additional paid-in capital
Additional paid-in capital
Conversion Of Convertible Preferred Stock
Additional paid-in capital
Series C Preferred Stock
Additional paid-in capital
AlmataBio Transaction
Accumulated other comprehensive income
Accumulated deficit
Balance at the beginning (in shares) at Dec. 31, 2023 0                                      
Balance at the beginning at Dec. 31, 2023 $ 0                                      
Increase (Decrease) in Temporary Equity [Roll Forward]                                        
Issuance of stock (in shares)             2,412 19,946 1 1                    
Issuance of common stock pursuant to ATM Program, net             $ 11,457                          
Retirement of Series C Preferred Stock in exchange for issuance of common stock (in shares) (8,648)                                      
Retirement of Series C Preferred Stock in exchange for issuance of common stock $ (9,799)                                      
Reclassification of Series C Preferred Stock from mezzanine equity to permanent equity (in shares)     (13,710)                                  
Reclassification of Series C Preferred Stock from mezzanine equity to permanent equity     $ (1,658)                                  
Balance at the end (in shares) at Dec. 31, 2024 2     1 1                              
Balance at the end at Dec. 31, 2024 $ 0     $ 0 $ 0                              
Balance at the beginning (in shares) at Dec. 31, 2023                     801,746                  
Balance at the beginning at Dec. 31, 2023 7,304                   $ 1     $ 0 $ 342,437       $ 0 $ (335,134)
Balance at the beginning (in shares) at Dec. 31, 2023                           0            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                        
Issuance of common stock through exercise of options (in shares)                     60,779                  
Issuance of common stock pursuant to AlmataBio Transaction (in shares)                         171,605              
Issuance of common stock in exchange for retirement of Series C Preferred Stock           $ 815                       $ 815    
Issuance of shares pursuant to warrant exercises (in shares)                     781,259 8,648,244   11,186            
Issuance of shares pursuant to warrant exercises 9,647 $ 9,798 133,019               $ 1 $ 8     9,646 $ 9,790 $ 133,019      
Reclassification of Series C Preferred Stock from mezzanine equity to permanent equity (in shares)                           13,710            
Reclassification of Series C Preferred Stock from mezzanine equity to permanent equity     $ 1,658                           $ 1,658      
Shares purchased through employee stock purchase plan (in shares)                     8,301                  
Shares purchased through employee stock purchase plan 68                           68          
Stock-based compensation 5,852                           5,852          
Net loss $ (35,129)                                     (35,129)
Balance at the end (in shares) at Dec. 31, 2024 10,471,934                   10,471,934                  
Balance at the end at Dec. 31, 2024 $ 133,032                   $ 10     $ 0 503,285       0 (370,263)
Balance at the end (in shares) at Dec. 31, 2024     24,896                     24,896            
Balance at the end (in shares) at Dec. 31, 2025 2     1 1                              
Balance at the end at Dec. 31, 2025 $ 0     $ 0 $ 0                              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                        
Issuance of common stock through exercise of options (in shares)     6,104               78,362                  
Issuance of common stock from exercise of stock options 774                           774          
Issuance of common stock pursuant to ATM Program, net 14,300                   $ 2       14,298          
Vesting or Restricted Stock Units net of shares withheld for taxes (in shares)                     162,019                  
Vesting of Restricted Stock Units, net of shares withheld for taxes (510)                           (510)          
Issuance of shares pursuant to warrant exercises           $ 0           $ 6     (6)          
Shares purchased through employee stock purchase plan (in shares)                     38,549                  
Shares purchased through employee stock purchase plan 23                           23          
Unrealized gain on investments, net 68                                   68  
Stock-based compensation 13,621                           13,621          
Net loss $ (78,259)                                     (78,259)
Balance at the end (in shares) at Dec. 31, 2025 18,512,757                   18,512,757                  
Balance at the end at Dec. 31, 2025 $ 83,049                   $ 18     $ 0 $ 531,485       $ 68 $ (448,522)
Balance at the end (in shares) at Dec. 31, 2025     18,792                     18,792